South Sudan
Tuberculosis profile
Population  2013 11 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.5 (2.9–6.5) 40 (26–58)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 32 (14–58) 286 (122–518)
Incidence  (includes HIV+TB) 17 (14–20) 146 (121–174)
Incidence (HIV+TB only) 3 (0.79–6.3) 27 (7–56)
Case detection, all forms (%) 39 (33–47)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
98 (5–270) 140 (1–280)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 028   175
Pulmonary, clinically diagnosed 2 125   0
Extrapulmonary 1 094   0
       
Total new and relapse 6 422    
Previously treated, excluding relapses 537    
Total cases notified 6 959    
Among 3 032 new cases:
111 (4%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 90 (3%) 0 (0%) 90
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 4 462 (64)
HIV-positive TB patients 669 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 491 (73)
HIV-positive TB patients on antiretroviral therapy (ART) 236 (35)
HIV-positive people screened for TB 9 230  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 52
Previously treated cases, excluding relapse, registered in 2012 40
HIV-positive TB cases, all types, registered in 2012 39
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.7
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 23
% Funded domestically <1%
% Funded internationally 25%
% Unfunded 74%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-05 Data: www.who.int/tb/data